Viewing nowCombinationEmpavex 12.5/1000 mg (Empagliflozin, Metformin Hydrochloride)
Empagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Seoul Pharmaceutical Co., Ltd.

MFDS item code 202501702 · Approved 2025.07.08 · Insurance code 652904770
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is prescribed to help control blood sugar levels in adults with type 2 diabetes using both empagliflozin and metformin. It is used as an adjunct to diet and exercise, enabling effective management of blood sugar levels. It is particularly suitable for patients whose blood sugar is not adequately controlled and should be used with caution in cases of comorbid cardiovascular disease. This medication aids in blood sugar management and improving the patient's overall health.
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Patients with renal impairment No dose adjustment is required in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl <45 ml/min or eGFR <45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use 2. Patients in Whom the Medicine Must Not Be Used, item 2)). Elderly patients Renal function and the risk of volume depletion should be considered in patients aged 75 years or older.
This medication can cause a rare side effect called severe lactic acidosis, so it should not be used in patients with impaired kidney function or acute illness. Caution is required when used with other hypoglycemic agents due to the risk of hypoglycemia. This medication should not be administered to patients with moderate or worse kidney function or conditions that can lead to acute kidney injury. It should also be avoided in cases of acute illnesses such as cardiovascular collapse, acute myocardial infarction, or sepsis. It should be temporarily discontinued before and after tests involving iodinated contrast agents, and resumed only after checking kidney function. If surgery is planned, discontinue this medication 48 hours before the procedure and resume after kidney function has returned to normal. It should not be used in patients with poor nutritional status, liver dysfunction, or in pregnant or breastfeeding women. During treatment, regular monitoring of kidney function and serum creatinine levels is necessary to catch any abnormalities. Be cautious of dehydration and hypotension in situations of fluid loss; the medication may be discontinued if necessary. This medication may increase the risk of urinary tract infections and genital infections, and symptoms should be treated immediately. Vitamin B12 levels may decrease, so regular monitoring is needed during long-term use. Excessive alcohol intake can heighten the risk of lactic acidosis, hence alcohol consumption should be avoided. Hypoglycemic symptoms may occur during treatment, especially in conjunction with insulin or sulfonylureas, necessitating dose adjustments. This medication is not recommended for children under 18 years and should be administered cautiously in elderly patients over 75 years. In cases of overdose, treatments such as dialysis might be necessary, so immediate medical attention is required. This medication should be stored out of reach of children and kept in its original container.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to avoid exposure to air and moisture. It is best kept at room temperature between 1 and 30 degrees Celsius.
A dark brownish purple, biconvex, oval film-coated tablet.
60 tablets/bottle, 60 tablets/box [10 tablets/PTP x 6]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Seoul Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.